Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.4K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

684
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
684
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

3.3K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complex Deep Neural Networks for Denoising Ultra-Fast Submillimeter T2*-weighted Imaging and Quantitative Susceptibility Mapping.

European journal of radiology artificial intelligence·2026
Same author

Multiple sclerosis as an asynchronous neuroinflammatory system.

Frontiers in immunology·2026
Same author

An Unsupervised Approach for Artifact Severity Scoring in Multi-Contrast MR Images.

Proceedings of machine learning research·2026
Same author

Challenges and future directions for multiple sclerosis after the 2024 McDonald diagnostic criteria.

Nature medicine·2026
Same author

Corrigendum to "A Pre-symptomatic phase of tumefactive multiple sclerosis mirrors radiologically isolated syndrome" [Multiple Sclerosis and Related Disorders 112 (2026) 107312].

Multiple sclerosis and related disorders·2026
Same author

Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes.

Annals of neurology·2026

Related Experiment Video

Updated: Apr 3, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K

Treatment of Multiple Sclerosis.

Ellen M Mowry, Darin T Okuda, Daniel Ontaneda

    Continuum (Minneapolis, Minn.)
    |April 2, 2026
    PubMed
    Summary

    Treating acute multiple sclerosis (MS) relapses with corticosteroids can speed recovery, but requires careful diagnosis. Choosing disease-modifying therapies for MS involves shared decision-making and monitoring for effectiveness and safety.

    Area of Science:

    • Neurology
    • Immunology
    • Clinical Therapeutics

    Background:

    • Multiple sclerosis (MS) relapses stem from acute inflammatory demyelination.
    • Symptoms may worsen due to systemic issues, not necessarily new MS activity.
    • Current treatment strategies for newly diagnosed or active MS are evolving.

    Purpose of the Study:

    • To review the evidence for treating acute MS relapses.
    • To guide the selection of disease-modifying therapies (DMTs) for various MS types.
    • To emphasize patient monitoring and shared decision-making in MS management.

    Main Methods:

    • Evidence synthesis of current treatment guidelines and clinical trial data.
    • Analysis of therapeutic approaches for relapsing MS, radiologically isolated syndrome, and progressive MS.

    More Related Videos

    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
    09:41

    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

    Published on: July 19, 2019

    12.2K
    Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
    08:51

    Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

    Published on: February 19, 2021

    10.1K

    Related Experiment Videos

    Last Updated: Apr 3, 2026

    Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
    09:38

    Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

    Published on: September 12, 2016

    13.0K
    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
    09:41

    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

    Published on: July 19, 2019

    12.2K
    Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
    08:51

    Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

    Published on: February 19, 2021

    10.1K
  • Discussion of diagnostic considerations for MS relapse symptoms.

    • Main Results:

    • High-dose corticosteroids can accelerate recovery from acute MS relapses.
    • Shared decision-making is crucial for selecting appropriate DMTs in active MS.
    • Ongoing monitoring for safety and efficacy is essential for all MS therapies.
    • Benefit from current DMTs may be limited in progressive MS without active disease.

    Conclusions:

    • Effective management of MS requires differentiating true relapses from other causes of symptom worsening.
    • Personalized treatment selection and vigilant monitoring are key to optimizing outcomes in MS.
    • Emerging data support the benefit of early MS therapy, particularly in the relapsing form.